Opendata, web and dolomites

MAINTRAC-Auto

MAINTRAC-Auto: Automatization and validation of a liquid biopsy assay “Maintrac-AUTO CTC-analyser” for predictive real time monitoring and success control of solid tumor cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAINTRAC-Auto project word cloud

Explore the words cloud of the MAINTRAC-Auto project. It provides you a very rough idea of what is the project "MAINTRAC-Auto" about.

track    sales    series    upscaling    disease    diagnostics    patient    regulatory    equivalence    clinically    progression    validation    adequately    maintenance    market    2020    death    care    suffering    reducing    assay    tumor    relapse    innovative    course    initial    forecasts    worldwide    treatment    families    commercially    automated    relevance    cancer    penetration    automatic    revenue    ctc    auto    acceptance    maintrac    health    big    individualize    manual    causes    assays    patients    circulating    prognosis    breast    meet    arise    reimbursement    ctcs    direct    therapies    efficiency    symptoms    clinical    indicator    meanwhile    launch    economic    ineffective    monitoring    diagnose    estimate    precision    innovation    individual    diseases    drastically    oncology    savings    therapy    cells    analyser    biomarker    primary    obvious    12bn    model    business    readiness    effectiveness    us    approved    public    substantially    specialists    implications    appropriate    offers    demand    standardized   

Project "MAINTRAC-Auto" data sheet

The following table provides information about the project.

Coordinator
SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH 

Organization address
address: KURPROMENADE 2
city: BAYREUTH
postcode: 95448
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.simfo.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH DE (BAYREUTH) coordinator 50˙000.00

Map

 Project objective

Worldwide cancer is one of the leading causes of death and the need for more effective therapies is crucial. New precision diagnostics can identify and characterize the disease to individualize the therapy throughout the course of cancer, like our clinically approved Maintrac-CTC assay. Maintrac-CTC can track circulating tumor cells (CTCs) even in primary cancer patients to estimate prognosis and diagnose relapse well before clinical symptoms arise. Meanwhile a fully automated Maintrac AUTO analyser was established and offers a standardized state-of-art biomarker system for direct and better monitoring of disease progression and effectiveness i.e. of the maintenance therapy in breast cancer. We aim to drastically increase both effectiveness (selection of treatment most adequately for individual cancer type and phase) and efficiency (early indicator for the response level to an initial therapy) to avoid ineffective therapies, savings cost for the health care system and substantially reducing patient suffering. The objectives of the innovation project are to achieve series-production readiness and launch the system commercially with the best business model. We aim for acceptance of Maintrac CTC assays by oncology specialists through clinical validation and to achieve reimbursement by public authorities for upscaling and market penetration. In phase 1 we will show equivalence of the automatic system to the established manual method and meet regulatory requirements. In addition business opportunities and appropriate sales model will be evaluated. Forecasts for overall CTC biomarker market estimate a big market with a high demand for innovative products with expected revenue potential of US$ 12bn in 2020. Due to the obvious relevance of cancer diseases for patients, their families as well as economic implications, Maintrac will have an important impact on future cancer disease management.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAINTRAC-AUTO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAINTRAC-AUTO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More